Cell Therapy Market size was valued at USD 5.2 Billion in 2023 and is poised to exceed USD 47.9 Billion by the end of 2036, registering over 21% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of cell therapy is assessed at USD 8.1 Billion.
It is believed that the rising incidence of cancer across the globe is driving this market expansion. The Food and Drug Administration (FDA) has approved CAR T-cell therapies, bringing them into the mainstream for the management of multiple myeloma, leukemia, and lymphomas.
As per the World Health Organization (WHO), it is anticipated that there will be over 35 million new cases of cancer in 2050, a 77% increase over the projected 20 million cases in 2022.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024–2036 |
|
CAGR |
21% |
|
Base Year Market Size (2023) |
USD 5.2 Billion |
|
Forecast Year Market Size (2036) |
USD 47.9 Billion |
|
Regional Scope |
|
Therapy Type (Allogeneic, Autologous)
Autologous segment is estimated to hold more than 92% cell therapy market share by 2036. The segment growth can be attributed to the rising burden of genetic disorders. It was reported in 2022 that every year, more than 200,000 newborns worldwide are born with sickle cell disease, accounting for about 4% of the global population.
Patient-specific autologous cell therapy shows potential in treating a broad range of inherited and acquired human disorders. Autologous cell therapy is a type of customized medicine in which sickness is treated with the patient's own genetically modified immune cells and has shown successful results in treating genetic abnormalities.
Therapeutic Area (Oncology, Cardiovascular Disease (CVD), Musculoskeletal Disorders, Dermatology)
Throughout the projected period, the oncology segment in cell therapy market is expected to grow at the fastest rate. The growing prevalence of blood cancer is the primary driver of the segment's growth. For instance, more than 1 million instances of blood cancer are reported globally each year, making up roughly 5% of all cancer cases.
The Food and Drug Administration has recognized CAR-T cell therapy as one of the most promising forms of blood cancer treatment through targeting and destroying cancer cells by stimulating the immune system.
Use (Clinical, Research)
For the forecast timeline, the research segment in cell therapy market is likely to register a significant revenue share aided by the rising popularity of stem cell therapy. Stem cell treatment is becoming a very promising and cutting-edge area of scientific study that has created new opportunities for patients with untreated diseases and disorders.
Since stem cell treatments are highly effective and have success rates as high as over 75%, their popularity has grown substantially.
The advancement of stem cell research has significant potential for the creation of innovative treatments for significant and common human illnesses. Stem cells are currently being investigated for their potential to restore brain damage and are being researched for the treatment of osteoarthritis, heart failure, type 1 diabetes, and amyotrophic lateral sclerosis, among other illnesses.
Our in-depth analysis of the market includes the following segments:
|
Therapy Type |
|
|
Therapeutic Area |
|
|
End-User |
|
|
Technology |
|
|
Use |
|
North American Market Statistics
North America in cell therapy market is estimated to hold more than 59% revenue share by 2036. The market growth in the region is also expected on account of growing advancements in medical research. The American healthcare system has made large financial investments in the production of pharmaceuticals and medical research, which is likely to result in continuous advancement in cell therapy technologies in the region.
Also, in 2022, U.S. health spending climbed by over 3% to reach around USD 4 trillion. This may serve as a model for assisting patients with lower incomes to finance additional gene and cell therapies in the region.
Canada has authorized more than 2 cellular therapy products in total for use in patient care as of 2021, which comprise the treatment of adult B-cell lymphoma, Graft V Host disease, and acute lymphoblastic leukemia (ALL) with stem cells.
APAC Market Analysis
The Asia Pacific region will also encounter huge growth for the cell therapy market during the forecast period and will hold the second position as it is the fastest-growing region in the world for gene and cell therapy trials led by the comparatively inexpensive cost of performing clinical trials, which has driven numerous international corporations to profit from the reduced expenses and greater patient volumes.
The region also leads the world in CAR-T trials, with China hosting more than 55% of all CAR-T trials conducted between 2015 and 2022.
Additionally, to obtain a competitive edge and fulfill the growing demand for cell therapies arising from the growing senior population in Japan prominent Japanese firms including Fujifilm, Takeda Pharmaceutical, and Astellas Pharma have entered into deals in the CAR T-Cell therapy field.
In February 2023, more than 12 cell therapies were licensed by the Ministry of Food and Drug Safety (MFDS) of South Korea.
The market for cell therapy consists of many key players who are launching various strategic initiatives to expand their market position in the industry.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?